Cigna Group (CI)
(Delayed Data from NYSE)
$354.47 USD
-0.04 (-0.01%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $354.44 -0.03 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Price, Consensus and EPS Surprise
CI 354.47 -0.04(-0.01%)
Will CI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CI
The Zacks Analyst Blog Highlights Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare
Cigna (CI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stay Ahead With 4 Healthcare Stocks Poised for Q1 Earnings Beat
Cigna (CI) Stock Dips While Market Gains: Key Facts
Here's Why Cigna (CI) is a Strong Momentum Stock
Other News for CI
New Report: Employers Play Critical Role in Curbing Today's Youth Mental Health Crisis
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
AbbVie stock slides 6% amid concerns about falling Humira sales
Evernorth announces Humira biosimilar available at $0 out of pocket for Accredo patients in June
AM Best Affirms Credit Ratings of The Cigna Group and Its Subsidiaries